Torasemide (Tablets) Instructions for Use
ATC Code
C03CA04 (Torasemide)
Active Substance
Torasemide (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Diuretic
Pharmacotherapeutic Group
Diuretics; “loop” diuretics; sulfonamides
Pharmacological Action
A “loop” diuretic. The primary mechanism of action is due to the reversible binding of torasemide to the sodium/chloride/potassium cotransporter located in the apical membrane of the thick ascending limb of the loop of Henle, resulting in a reduction or complete inhibition of sodium ion reabsorption and a decrease in the osmotic pressure of the intracellular fluid and water reabsorption.
Torasemide causes hypokalemia to a lesser extent than furosemide, while exhibiting greater activity and a longer duration of action.
The diuretic effect develops approximately within an hour after oral administration, reaches its maximum in 3-6 hours, and lasts from 8 to 10 hours.
It reduces systolic and diastolic blood pressure in the supine and standing positions.
Pharmacokinetics
After oral administration, Torasemide is absorbed from the gastrointestinal tract with a limited first-pass effect through the liver. Cmax in blood plasma is achieved within 1.5 hours after oral administration. Food intake does not significantly affect absorption. Impaired renal and/or liver function does not affect absorption.
More than 99% of torasemide is bound to plasma proteins.
Vd in healthy volunteers and in patients with mild to moderate renal failure or chronic heart failure ranges from 12 to 15 L. In patients with liver cirrhosis, Vd doubles.
It is metabolized in the liver by the isoenzyme CYP2C9 to form three metabolites.
The main metabolite is a carboxylic acid derivative and is pharmacologically inactive. The other two metabolites, which are formed in the body in insignificant amounts, possess some diuretic activity, but their concentration is too low to exert any significant clinical effect.
The T1/2 of torasemide in healthy volunteers is 4 hours. About 80% of the orally administered dose is excreted by the kidneys as metabolites and about 20% unchanged (in patients with normal renal function). The total clearance of torasemide is 41 ml/min and renal clearance is about 10 ml/min, which corresponds to approximately 25% of the total.
In patients with decompensated chronic heart failure, the hepatic and renal clearance of the drug is reduced. In such patients, the total clearance of torasemide is 50% lower than in healthy volunteers, and the T1/2 and total bioavailability are correspondingly higher.
In patients with renal failure, the renal clearance of torasemide is significantly reduced, but this does not affect the total clearance. The diuretic effect in renal failure can be achieved by using high doses. The total clearance of torasemide and T1/2 remain at the same level in case of reduced renal function, due to metabolism in the liver.
In patients with liver cirrhosis, Vd, T1/2, and renal clearance are increased, but the total clearance remains unchanged.
The pharmacokinetic profile of torasemide in elderly patients is similar to that in young patients, except for a decrease in the renal clearance of the drug due to the characteristic age-related decline in renal function in elderly patients. The total clearance and T1/2 do not change.
Indications
Edematous syndrome of various origins, including in chronic heart failure, liver and kidney diseases.
Arterial hypertension.
ICD codes
| ICD-10 code | Indication |
| I10 | Essential [primary] hypertension |
| I50.0 | Congestive heart failure |
| K74 | Fibrosis and cirrhosis of liver |
| N03 | Chronic nephritic syndrome |
| N04 | Nephrotic syndrome |
| N18 | Chronic kidney disease |
| R60 | Edema, not elsewhere classified |
| ICD-11 code | Indication |
| BA00.Z | Essential hypertension, unspecified |
| BD10 | Congestive heart failure |
| DB93 | Fibrosis or cirrhosis of liver |
| GB40 | Nephritic syndrome |
| GB41 | Nephrotic syndrome |
| GB61.Z | Chronic kidney disease, unspecified stage |
| MG29.Z | Edema, unspecified |
| GB40 | Nephritic syndrome |
| XT8W | Chronic course |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take tablets orally, once daily, with or without food.
For edema in chronic heart failure, renal or hepatic disease, initiate therapy at 10 mg or 20 mg once daily.
For arterial hypertension, initiate therapy at 5 mg once daily. Titrate dose to achieve target blood pressure, potentially increasing to 10 mg daily after 4-6 weeks if response is inadequate.
Adjust the dosage based on individual patient response, clinical condition, and electrolyte balance. For patients with severe renal impairment or hepatic cirrhosis, consider initiating therapy at a higher dose; monitor closely for excessive diuresis and electrolyte disturbances.
Do not exceed a single dose of 40 mg; safety and efficacy of doses above 40 mg are not established.
Administer for the duration prescribed; for edema, continue until the condition resolves. For hypertension, therapy is typically long-term.
Monitor serum electrolytes, particularly potassium and sodium, renal function, and blood pressure regularly, especially during initial therapy and after dose adjustments. In patients at high risk for hypokalemia, consider concomitant potassium supplementation or a potassium-sparing diuretic.
Adverse Reactions
Metabolism: infrequently – hypercholesterolemia, hypertriglyceridemia, polydipsia.
Nervous system: frequently – dizziness, headache, drowsiness; infrequently – muscle cramps of the lower extremities; frequency unknown – confusion, fainting, paresthesia in the limbs.
Cardiovascular system: infrequently – extrasystole, tachycardia, palpitations, facial flushing; frequency unknown – excessive arterial hypotension, deep vein thrombosis, thromboembolism, hypovolemia.
Respiratory system: infrequently – nosebleeds.
Digestive system: frequently – diarrhea; infrequently – abdominal pain, flatulence; frequency unknown – nausea, vomiting, loss of appetite, pancreatitis, dyspeptic symptoms.
Kidneys and urinary tract: frequently – increased frequency of urination, polyuria, nocturia; infrequently – frequent urge to urinate; frequency unknown – urinary retention (in patients with urinary tract obstruction), increased blood urea and creatinine concentrations.
Laboratory parameters: infrequently – increased platelet count; frequency unknown – hyperglycemia, hyperuricemia, hypokalemia, decreased red blood cell, white blood cell and platelet counts, slight increase in blood alkaline phosphatase activity, increased activity of some liver enzymes (e.g., GGT), hyponatremia, hypochloremia, metabolic alkalosis.
Sensory organs: frequency unknown – visual disturbances, ringing in the ears and hearing loss (usually reversible).
Skin: frequency unknown – skin itching, rash, photosensitivity.
Other: infrequently – asthenia, weakness, thirst, hyperactivity, nervousness, increased fatigue.
Contraindications
Anuria; hepatic coma and precoma; refractory hypokalemia; refractory hyponatremia; dehydration; severe impairment of urine outflow of any etiology (including unilateral urinary tract involvement); glycoside intoxication; acute glomerulonephritis; sinoatrial and AV block of II and III degree; children and adolescents under 18 years of age; pregnancy; hypersensitivity to torasemide; allergy to sulfonamides (sulfonamide antimicrobials or sulfonylurea drugs).
Use in Pregnancy and Lactation
Contraindicated during pregnancy. Use with caution during lactation (breastfeeding).
Special Precautions
With caution: arterial hypotension; hypovolemia (with or without arterial hypotension); impaired urine outflow (benign prostatic hyperplasia, urethral stricture or hydronephrosis); history of ventricular arrhythmia; acute myocardial infarction (increased risk of cardiogenic shock); diarrhea; pancreatitis; diabetes mellitus (reduced glucose tolerance); liver disease complicated by cirrhosis and ascites, renal failure, hepatorenal syndrome; gout, hyperuricemia; anemia; simultaneous use of cardiac glycosides, aminoglycosides or cephalosporins, corticosteroids or ACTH; hypokalemia; hyponatremia; lactation period.
Patients with hypersensitivity to sulfonamides and sulfonylurea derivatives may have cross-sensitivity to torasemide.
In patients, especially at the beginning of treatment with torasemide and in elderly individuals, monitoring of electrolyte balance, volume and concentration of circulating blood is recommended.
During long-term treatment with torasemide, regular monitoring of electrolyte balance (especially potassium levels), glucose, uric acid, creatinine, lipids, and blood cellular components is recommended.
For patients receiving Torasemide in high doses, it is not advisable to restrict salt intake to avoid the development of hyponatremia and metabolic alkalosis.
The risk of hypokalemia is greatest in patients with liver cirrhosis, pronounced diuresis, insufficient intake of electrolytes with food, as well as during simultaneous treatment with corticosteroids or ACTH.
An increased risk of water-electrolyte balance disorders is noted in patients with renal failure. During course treatment, it is necessary to periodically monitor the concentration of plasma electrolytes (including sodium, calcium, potassium, magnesium), acid-base status, residual nitrogen, creatinine, uric acid and, if necessary, carry out appropriate corrective therapy (more frequently in patients with frequent vomiting and against the background of parenterally administered fluids).
In patients with developed water-electrolyte disorders, hypovolemia or prerenal azotemia, laboratory data may include: hyper- or hyponatremia, hyper- or hypochloremia, hyper- or hypokalemia, acid-base balance disorders and increased blood urea levels. If these disorders occur, it is necessary to stop taking torasemide until normal values are restored, and then resume treatment with torasemide at a lower dose. If azotemia and oliguria appear or worsen in patients with severe progressive kidney diseases, it is recommended to suspend treatment.
Selection of the dosage regimen in patients with ascites due to liver cirrhosis should be carried out in a hospital setting (water-electrolyte balance disorders can lead to the development of hepatic coma). This category of patients requires regular monitoring of plasma electrolytes.
To prevent hypokalemia, the use of potassium preparations and potassium-sparing diuretics (primarily spironolactone) is recommended, as well as adherence to a diet rich in potassium.
The use of torasemide can cause an exacerbation of gout.
In patients with diabetes mellitus or reduced glucose tolerance, periodic monitoring of blood and urine glucose concentration is required.
In patients with prostatic hyperplasia, narrowing of the ureters, control of diuresis is necessary due to the possibility of acute urinary retention.
In patients with cardiovascular diseases, especially those taking cardiac glycosides, diuretic-induced hypokalemia can cause arrhythmias.
Effect on the ability to drive vehicles and mechanisms
During the treatment period, patients should avoid engaging in potentially hazardous activities that require increased attention and speed of psychomotor reactions.
Drug Interactions
Torasemide increases the toxicity of cardiac glycosides.
With simultaneous use with mineralo- and glucocorticoids, laxatives, an increase in potassium excretion is possible.
Torasemide enhances the effect of antihypertensive drugs.
Torasemide, especially in high doses, may enhance the nephrotoxic and ototoxic effects of aminoglycosides, antibiotics, platinum drugs, cephalosporins.
Torasemide may enhance the effect of curare-like muscle relaxants and theophylline.
With simultaneous use of salicylates in high doses, an increase in their toxic effect is possible.
Torasemide weakens the effect of hypoglycemic drugs.
Sequential or simultaneous administration of torasemide with ACE inhibitors may lead to a short-term drop in blood pressure. This can be avoided by reducing the initial dose of the ACE inhibitor or reducing the dose of torasemide (or temporarily discontinuing it).
NSAIDs and probenecid may reduce the diuretic and hypotensive effect of torasemide.
The bioavailability and, consequently, the effectiveness of torasemide may be reduced when used in combination with cholestyramine.
Torasemide may increase the toxicity of lithium drugs and the ototoxicity of ethacrynic acid.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Tablets 5 mg: 30, 60, or 100 pcs.
Marketing Authorization Holder
Hetero Labs, Limited (India)
Manufactured By
Hetero Labs, Limited (India)
Or
Makiz-Pharma, LLC (Russia)
Dosage Form
 |
Torasemide | Tablets 5 mg: 30, 60, or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, oval, biconvex, with a score; on the side with the score, engraving “56”, on the opposite side, engraving “H”.
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: lactose monohydrate – 79 mg, microcrystalline cellulose (MCC-101) – 10 mg, crospovidone – 3 mg, povidone K30 – 2 mg, magnesium stearate – 1 mg.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
60 pcs. – jars (1) – cardboard packs.
100 pcs. – jars (1) – cardboard packs.
100 pcs. – bottles (1) – cardboard packs.
Tablets 10 mg: 30, 60, or 100 pcs.
Marketing Authorization Holder
Hetero Labs, Limited (India)
Manufactured By
Hetero Labs, Limited (India)
Or
Makiz-Pharma, LLC (Russia)
Dosage Form
|
Torasemide | Tablets 10 mg: 30, 60, or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, oval, biconvex, with a score; on the side with the score, engraving “57”, on the opposite side, engraving “H”.
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: lactose monohydrate – 158 mg, microcrystalline cellulose (MCC-101) – 20 mg, crospovidone – 6 mg, povidone K30 – 4 mg, magnesium stearate – 2 mg.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
60 pcs. – jars (1) – cardboard packs.
100 pcs. – jars (1) – cardboard packs.
100 pcs. – bottles (1) – cardboard packs.
Tablets 5 mg: 10, 20, 30, 40, 50, 60, 70, 80, or 90 pcs.
Tablets 10 mg: 10, 20, 30, 40, 50, 60, 70, 80, or 90 pcs.
Marketing Authorization Holder
Aliym, JSC (Russia)
Dosage Forms
|
Torasemide | Tablets 5 mg: 10, 20, 30, 40, 50, 60, 70, 80, or 90 pcs. |
| Tablets 10 mg: 10, 20, 30, 40, 50, 60, 70, 80, or 90 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, oblong in shape with rounded ends, biconvex, with a score.
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: lactose monohydrate, corn starch, sodium carboxymethyl starch (sodium starch glycolate), colloidal silicon dioxide (aerosil), magnesium stearate.
10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
10 pcs. – blister packs (7) – cardboard packs.
10 pcs. – blister packs (8) – cardboard packs.
10 pcs. – blister packs (9) – cardboard packs.
Tablets white or almost white, round, flat-cylindrical, with a bevel and a score.
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: lactose monohydrate, corn starch, sodium carboxymethyl starch (sodium starch glycolate), colloidal silicon dioxide (aerosil), magnesium stearate.
10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
10 pcs. – blister packs (7) – cardboard packs.
10 pcs. – blister packs (8) – cardboard packs.
10 pcs. – blister packs (9) – cardboard packs.
Tablets 5 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 180, 200, or 300 pcs.
Tablets 10 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 180, 200, or 300 pcs.
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Forms
|
Torasemide | Tablets 5 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 180, 200, or 300 pcs. |
| Tablets 10 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 180, 200, or 300 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, round, flat-cylindrical, with a score and a bevel.
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: lactose monohydrate – 90.4 mg, sodium carboxymethyl starch – 3 mg, magnesium stearate – 0.8 mg, colloidal silicon dioxide – 0.8 mg.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
20 pcs. – contour cell packaging (1) – cardboard packs.
20 pcs. – contour cell packaging (2) – cardboard packs.
20 pcs. – contour cell packaging (3) – cardboard packs.
20 pcs. – contour cell packaging (4) – cardboard packs.
20 pcs. – contour cell packaging (5) – cardboard packs.
20 pcs. – contour cell packaging (6) – cardboard packs.
20 pcs. – contour cell packaging (10) – cardboard packs.
30 pcs. – contour cell packaging (1) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
30 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – contour cell packaging (4) – cardboard packs.
30 pcs. – contour cell packaging (5) – cardboard packs.
30 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – contour cell packaging (10) – cardboard packs.
Tablets white or almost white, round, flat-cylindrical, with a cross-shaped score and a bevel.
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: lactose monohydrate – 180.8 mg, sodium carboxymethyl starch – 6 mg, magnesium stearate – 1.6 mg, colloidal silicon dioxide – 1.6 mg.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
20 pcs. – contour cell packaging (1) – cardboard packs.
20 pcs. – contour cell packaging (2) – cardboard packs.
20 pcs. – contour cell packaging (3) – cardboard packs.
20 pcs. – contour cell packaging (4) – cardboard packs.
20 pcs. – contour cell packaging (5) – cardboard packs.
20 pcs. – contour cell packaging (6) – cardboard packs.
20 pcs. – contour cell packaging (10) – cardboard packs.
30 pcs. – contour cell packaging (1) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
30 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – contour cell packaging (4) – cardboard packs.
30 pcs. – contour cell packaging (5) – cardboard packs.
30 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – contour cell packaging (10) – cardboard packs.
Tablets 5 mg: 20, 30, 60, or 100 pcs.
Tablets 10 mg: 20, 30, 60, or 100 pcs.
Marketing Authorization Holder
Beryozovsky Pharmaceutical Plant, CJSC (Russia)
Dosage Forms
|
Torasemide | Tablets 5 mg: 20, 30, 60, or 100 pcs. |
| Tablets 10 mg: 20, 30, 60, or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, round, flat-cylindrical in shape, with a bevel and a score.
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: microcrystalline cellulose – 44 mg, lactose monohydrate – 26.4 mg, povidone – 1.6 mg, sodium carboxymethyl starch (sodium starch glycolate) – 2.4 mg, magnesium stearate – 0.6 mg.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
100 pcs. – jars (1) – cardboard packs.
Tablets white or almost white, round, flat-cylindrical in shape, with a bevel and a score.
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: microcrystalline cellulose – 88 mg, lactose monohydrate – 52.8 mg, povidone – 3.2 mg, sodium carboxymethyl starch (sodium starch glycolate) – 4.8 mg, magnesium stearate – 1.2 mg.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
100 pcs. – jars (1) – cardboard packs.
Tablets 2.5 mg: 20, 30, 40, 50, 60, or 90 pcs.
Tablets 5 mg: 20, 30, 40, 50, 60, or 90 pcs.
Tablets 10 mg: 20, 30, 40, 50, 60, or 90 pcs.
Marketing Authorization Holder
Pranapharm, LLC (Russia)
Dosage Forms
|
Torasemide | Tablets 2.5 mg: 20, 30, 40, 50, 60, or 90 pcs. |
| Tablets 5 mg: 20, 30, 40, 50, 60, or 90 pcs. | ||
| Tablets 10 mg: 20, 30, 40, 50, 60, or 90 pcs. |
Dosage Form, Packaging, and Composition
Tablets white, round, biconvex, without a score.
| 1 tab. | |
| Torasemide | 2.5 mg |
Excipients: lactose monohydrate, microcrystalline cellulose (type 102), povidone K-25, sodium starch glycolate (type A), colloidal silicon dioxide, magnesium stearate.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
Tablets white, round, flat-cylindrical, with a bevel, without a score.
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: lactose monohydrate, microcrystalline cellulose (type 102), povidone K-25, sodium starch glycolate (type A), colloidal silicon dioxide, magnesium stearate.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
Tablets white, round, flat-cylindrical, with a bevel and a score.
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: lactose monohydrate, microcrystalline cellulose (type 102), povidone K-25, sodium starch glycolate (type A), colloidal silicon dioxide, magnesium stearate.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
Tablets 5 mg: 20, 30, 60 or 90 pcs.
Tablets 10 mg: 20, 30, 60 or 90 pcs.
Marketing Authorization Holder
Pharmproekt, JSC (Russia)
Manufactured By
Pharmproekt, JSC (Russia)
Dosage Forms
|
Torasemide | Tablets 5 mg: 20, 30, 60 or 90 pcs. |
| Tablets 10 mg: 20, 30, 60 or 90 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, round, flat-cylindrical, with a bevel and a score.
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: mannitol – 52 mg, microcrystalline cellulose – 37.6 mg, corn starch pregelatinized – 37 mg, croscarmellose sodium – 7 mg, colloidal silicon dioxide – 0.7 mg, magnesium stearate – 0.7 mg.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
Tablets white or almost white, round, flat-cylindrical, with a bevel and a score.
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: mannitol – 78 mg, microcrystalline cellulose – 56 mg, corn starch pregelatinized – 53.5 mg, croscarmellose sodium – 10.5 mg, colloidal silicon dioxide – 1 mg, magnesium stearate – 1 mg.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
Tablets 5 mg: 20 or 60 pcs.
Tablets 10 mg: 20 or 60 pcs.
Marketing Authorization Holder
Canonpharma Production, CJS (Russia)
Dosage Forms
|
Torasemide Canon | Tablets 5 mg: 20 or 60 pcs. |
| Tablets 10 mg: 20 or 60 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, round, biconvex, with a score; slight marbling is allowed.
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: corn starch pregelatinized – 37 mg, colloidal silicon dioxide – 0.7 mg, croscarmellose sodium – 7 mg, mannitol – 52 mg, magnesium stearate – 0.7 mg, microcrystalline cellulose – 37.6 mg.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
Tablets white or almost white, round, biconvex, with a score; slight marbling is allowed.
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: corn starch pregelatinized – 53.5 mg, colloidal silicon dioxide – 1 mg, croscarmellose sodium – 10.5 mg, mannitol – 78 mg, magnesium stearate – 1 mg, microcrystalline cellulose – 56 mg.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
Tablets 5 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.
Tablets 10 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs.
Marketing Authorization Holder
Medisorb, JSC (Russia)
Dosage Forms
|
Torasemide Medisorb | Tablets 5 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs. |
| Tablets 10 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 49, 50, 56, 60, 63, 70, 80, 84, 90, 98, 100, 112, 126, or 140 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, round, flat-cylindrical, with a score on one side and a bevel on both sides.
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: lactose monohydrate, potato starch, talc, magnesium stearate.
7 pcs. – contour cell packaging (1) – cardboard packs.
7 pcs. – contour cell packaging (2) – cardboard packs.
7 pcs. – contour cell packaging (3) – cardboard packs.
7 pcs. – contour cell packaging (4) – cardboard packs.
7 pcs. – contour cell packaging (5) – cardboard packs.
7 pcs. – contour cell packaging (6) – cardboard packs.
7 pcs. – contour cell packaging (7) – cardboard packs.
7 pcs. – contour cell packaging (8) – cardboard packs.
7 pcs. – contour cell packaging (9) – cardboard packs.
7 pcs. – contour cell packaging (10) – cardboard packs.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (7) – cardboard packs.
10 pcs. – contour cell packaging (8) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
14 pcs. – contour cell packaging (1) – cardboard packs.
14 pcs. – contour cell packaging (2) – cardboard packs.
14 pcs. – contour cell packaging (3) – cardboard packs.
14 pcs. – contour cell packaging (4) – cardboard packs.
14 pcs. – contour cell packaging (5) – cardboard packs.
14 pcs. – contour cell packaging (6) – cardboard packs.
14 pcs. – contour cell packaging (7) – cardboard packs.
14 pcs. – contour cell packaging (8) – cardboard packs.
14 pcs. – contour cell packaging (9) – cardboard packs.
14 pcs. – contour cell packaging (10) – cardboard packs.
Tablets white or almost white, round, flat-cylindrical, with a score on one side and a bevel on both sides.
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: lactose monohydrate, potato starch, talc, magnesium stearate.
7 pcs. – contour cell packaging (1) – cardboard packs.
7 pcs. – contour cell packaging (2) – cardboard packs.
7 pcs. – contour cell packaging (3) – cardboard packs.
7 pcs. – contour cell packaging (4) – cardboard packs.
7 pcs. – contour cell packaging (5) – cardboard packs.
7 pcs. – contour cell packaging (6) – cardboard packs.
7 pcs. – contour cell packaging (7) – cardboard packs.
7 pcs. – contour cell packaging (8) – cardboard packs.
7 pcs. – contour cell packaging (9) – cardboard packs.
7 pcs. – contour cell packaging (10) – cardboard packs.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (7) – cardboard packs.
10 pcs. – contour cell packaging (8) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
14 pcs. – contour cell packaging (1) – cardboard packs.
14 pcs. – contour cell packaging (2) – cardboard packs.
14 pcs. – contour cell packaging (3) – cardboard packs.
14 pcs. – contour cell packaging (4) – cardboard packs.
14 pcs. – contour cell packaging (5) – cardboard packs.
14 pcs. – contour cell packaging (6) – cardboard packs.
14 pcs. – contour cell packaging (7) – cardboard packs.
14 pcs. – contour cell packaging (8) – cardboard packs.
14 pcs. – contour cell packaging (9) – cardboard packs.
14 pcs. – contour cell packaging (10) – cardboard packs.
Tablets 10 mg
Marketing Authorization Holder
Idea Pharm LLC (Russia)
Manufactured By
Pharmacor Production, LLC (Russia)
Dosage Form
|
Torasemide-Ideya Farm | Tablets 10 mg |
Dosage Form, Packaging, and Composition
Tablets
| 1 tab. | |
| Torasemide | 10 mg |
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
Tablets 5 mg: 20, 30, or 60 pcs.
Tablets 10 mg: 20, 30, or 60 pcs.
Marketing Authorization Holder
Teva Pharmaceutical Industries, Ltd. (Israel)
Manufactured By
Pliva Hrvatska, d.o.o. (Croatia)
Dosage Forms
|
Torasemide-Teva | Tablets 5 mg: 20, 30, or 60 pcs. |
| Tablets 10 mg: 20, 30, or 60 pcs. |
Dosage Form, Packaging, and Composition
Tablets
| 1 tab. | |
| Torasemide | 5 mg |
Excipients: lactose monohydrate, corn starch, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate.
10 pcs. – blisters made of PVC/aluminum foil (2, 3, or 6) – cardboard packs.
Tablets
| 1 tab. | |
| Torasemide | 10 mg |
Excipients: lactose monohydrate, corn starch, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate.
10 pcs. – blisters made of PVC/aluminum foil (2, 3, or 6) – cardboard packs.
![Torasemide [Tablets] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Torasemide [Tablets] 2")